Outlook Therapeutics® Gains European Commission Approval for Marketing LYTENAVA™ (bevacizumab gamma) to Treat Wet AMD.

May 31st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration has granted approval to Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of specific rare conditions.

In the TROPION-Lung01 Phase III trial, datopotamab deruxtecan significantly improved overall survival compared to chemotherapy in patients with advanced nonsquamous non-small cell lung cancer.

Sarclisa received FDA priority review for treating newly diagnosed multiple myeloma patients ineligible for transplant.

Rise Therapeutics has made a significant step forward by enrolling the first participant in its Phase 1 clinical trial for R-2487, a new oral immunotherapy for rheumatoid arthritis (RA).

Kiromic BioPharma, Inc. has announced promising initial findings from its Phase 1 clinical study of Deltacel™ in treating advanced non-small cell lung cancer (NSCLC).

Eilean Therapeutics announced that it has received approval from the AHREC to commence human trials for eiletoclax, a selective and powerful BCL2 inhibitor, in its Phase 1 clinical program.

Eilean Therapeutics LLC has successfully concluded a Phase 1 clinical trial for a drug named lomonitinib and is now starting a multiple ascending dose Phase 1 trial.

ARMGO Pharma has announced the successful results of a Phase 1b clinical trial for Rycal® ARM210, a treatment aimed at Ryanodine Receptor 1 Related Myopathies (RYR1-RM).

FDA has cleared Gracell’s Investigational New Drug (IND) application, allowing the Company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma (ELMM).

The COVID-19 pandemic has significantly transformed the healthcare industry, particularly in the realm of pharmaceutical clinical trials.